JP2006519823A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006519823A5 JP2006519823A5 JP2006505920A JP2006505920A JP2006519823A5 JP 2006519823 A5 JP2006519823 A5 JP 2006519823A5 JP 2006505920 A JP2006505920 A JP 2006505920A JP 2006505920 A JP2006505920 A JP 2006505920A JP 2006519823 A5 JP2006519823 A5 JP 2006519823A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- pharmaceutical composition
- composition according
- prevention
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002193 Pain Diseases 0.000 claims description 49
- 230000002265 prevention Effects 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 208000000450 Pelvic Pain Diseases 0.000 claims description 8
- 206010058019 Cancer Pain Diseases 0.000 claims description 7
- 208000004454 Hyperalgesia Diseases 0.000 claims description 7
- 208000035154 Hyperesthesia Diseases 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- 208000004296 neuralgia Diseases 0.000 claims description 7
- 208000021722 neuropathic pain Diseases 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 208000012124 AIDS-related disease Diseases 0.000 claims description 6
- 208000008035 Back Pain Diseases 0.000 claims description 6
- 208000001640 Fibromyalgia Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 6
- 208000004550 Postoperative Pain Diseases 0.000 claims description 5
- 230000001363 autoimmune Effects 0.000 claims description 5
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 4
- 208000006820 Arthralgia Diseases 0.000 claims description 4
- 206010006811 Bursitis Diseases 0.000 claims description 4
- 206010008479 Chest Pain Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 208000007514 Herpes zoster Diseases 0.000 claims description 4
- 208000007914 Labor Pain Diseases 0.000 claims description 4
- 208000008930 Low Back Pain Diseases 0.000 claims description 4
- 206010028836 Neck pain Diseases 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 4
- 206010061339 Perineal pain Diseases 0.000 claims description 4
- 208000004983 Phantom Limb Diseases 0.000 claims description 4
- 206010056238 Phantom pain Diseases 0.000 claims description 4
- 206010036105 Polyneuropathy Diseases 0.000 claims description 4
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 4
- 206010038419 Renal colic Diseases 0.000 claims description 4
- 206010039203 Road traffic accident Diseases 0.000 claims description 4
- 208000008765 Sciatica Diseases 0.000 claims description 4
- 208000000491 Tendinopathy Diseases 0.000 claims description 4
- 206010043255 Tendonitis Diseases 0.000 claims description 4
- 208000026816 acute arthritis Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 201000003229 acute pancreatitis Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 230000007824 polyneuropathy Effects 0.000 claims description 4
- 208000005198 spinal stenosis Diseases 0.000 claims description 4
- 201000004415 tendinitis Diseases 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 206010063094 Cerebral malaria Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 3
- 208000012659 Joint disease Diseases 0.000 claims description 3
- 206010027202 Meningitis bacterial Diseases 0.000 claims description 3
- 208000000112 Myalgia Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 206010037660 Pyrexia Diseases 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 201000010001 Silicosis Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 230000002917 arthritic effect Effects 0.000 claims description 3
- 201000009904 bacterial meningitis Diseases 0.000 claims description 3
- 208000019664 bone resorption disease Diseases 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 208000011379 keloid formation Diseases 0.000 claims description 3
- 201000003866 lung sarcoma Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 230000008816 organ damage Effects 0.000 claims description 3
- 230000010410 reperfusion Effects 0.000 claims description 3
- 231100000241 scar Toxicity 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 230000002123 temporal effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 210000003205 muscle Anatomy 0.000 claims 4
- 210000005036 nerve Anatomy 0.000 claims 4
- 230000001953 sensory effect Effects 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 206010050219 Lumbar radiculopathy Diseases 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 208000013465 muscle pain Diseases 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- 231100000827 tissue damage Toxicity 0.000 claims 2
- 230000009772 tissue formation Effects 0.000 claims 2
- AJACDNCVEGIBNA-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-amino-2-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(OC)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O AJACDNCVEGIBNA-KQYNXXCUSA-N 0.000 claims 1
- AJACDNCVEGIBNA-UHFFFAOYSA-N 2-Methoxyadenosine Natural products C12=NC(OC)=NC(N)=C2N=CN1C1OC(CO)C(O)C1O AJACDNCVEGIBNA-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 description 2
- 206010037779 Radiculopathy Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000917 hyperalgesic effect Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 description 1
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 description 1
- 230000003070 anti-hyperalgesia Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0305149.7A GB0305149D0 (en) | 2003-03-07 | 2003-03-07 | Compounds for the treatment of pain |
| PCT/GB2004/000935 WO2004078183A1 (en) | 2003-03-07 | 2004-03-05 | Compounds for the treatment of pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006519823A JP2006519823A (ja) | 2006-08-31 |
| JP2006519823A5 true JP2006519823A5 (enExample) | 2011-06-02 |
Family
ID=9954247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006505920A Pending JP2006519823A (ja) | 2003-03-07 | 2004-03-05 | 疼痛治療のための化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7759321B2 (enExample) |
| EP (1) | EP1603577B1 (enExample) |
| JP (1) | JP2006519823A (enExample) |
| KR (1) | KR20050115273A (enExample) |
| CN (1) | CN100579533C (enExample) |
| AT (1) | ATE401087T1 (enExample) |
| AU (1) | AU2004216889B2 (enExample) |
| CA (1) | CA2514098A1 (enExample) |
| CY (1) | CY1108416T1 (enExample) |
| DE (1) | DE602004015085D1 (enExample) |
| DK (1) | DK1603577T3 (enExample) |
| ES (1) | ES2310288T3 (enExample) |
| GB (1) | GB0305149D0 (enExample) |
| NO (1) | NO20054476L (enExample) |
| NZ (1) | NZ541521A (enExample) |
| PL (1) | PL1603577T3 (enExample) |
| PT (1) | PT1603577E (enExample) |
| SI (1) | SI1603577T1 (enExample) |
| WO (1) | WO2004078183A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0228723D0 (en) * | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
| GB0305150D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Use of therapeutic compounds |
| GB0305153D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Identification of therapeutic compounds |
| SG144146A1 (en) * | 2004-03-05 | 2008-07-29 | Cambridge Biotechnology Ltd | Adenosine receptor agonists |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| US8399400B2 (en) | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| CN1947717B (zh) * | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
| GB0610867D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| AU2007263726A1 (en) | 2006-06-27 | 2008-01-03 | Biovitrum Ab (Publ) | Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists |
| AU2007263727A1 (en) | 2006-06-27 | 2008-01-03 | Biovitrum Ab (Publ) | 2-0'-methyladen0sine derivatives and their use as agonists or antagonists of an adenosine receptor |
| NZ573308A (en) * | 2006-06-27 | 2012-02-24 | Biovitrum Ab Publ | Adenosine derivatives for the treatment of pain |
| US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| CN103342727A (zh) * | 2013-07-01 | 2013-10-09 | 淮海工学院 | 一种2-甲氧基腺苷的合成方法 |
| JP6440240B2 (ja) * | 2014-02-19 | 2018-12-19 | 国立大学法人富山大学 | 末梢神経障害誘発感覚異常を改善する外用剤 |
| CN114616230A (zh) * | 2019-07-31 | 2022-06-10 | 海洋生物技术与海洋资源有限公司 | 黄烷类似物化合物及其在治疗慢性和急性疼痛中的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE792155A (fr) * | 1971-12-01 | 1973-05-30 | Takeda Chemical Industries Ltd | Nouveaux derives de l'adenosine et leur procede de production |
| JPS4861498A (enExample) | 1971-12-01 | 1973-08-28 | ||
| DE2359536C2 (de) * | 1972-12-08 | 1984-08-02 | Takeda Chemical Industries, Ltd., Osaka | 2,6-Diaminonebularinderivate |
| JPS5461195A (en) * | 1977-10-21 | 1979-05-17 | Takeda Chem Ind Ltd | N2-substituted phenyl-2,6-diaminonebularin |
| JPS5461194A (en) * | 1977-10-21 | 1979-05-17 | Takeda Chem Ind Ltd | Preparation of n22substituted 2*66diaminonebularin |
| US4705758A (en) * | 1984-06-19 | 1987-11-10 | Warner-Lambert Company | Adenosine receptor assay and kit |
| US5679650A (en) * | 1993-11-24 | 1997-10-21 | Fukunaga; Atsuo F. | Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine |
| US5677290A (en) * | 1990-05-10 | 1997-10-14 | Fukunaga; Atsuo F. | Therapeutic use of adenosine compounds as surgical anesthetics |
| US5683989A (en) * | 1993-12-17 | 1997-11-04 | Novo Nordisk A/S | Treatment of ischemias by administration of 2,N6 -substituted adenosines |
| HUT75338A (en) * | 1994-05-10 | 1997-05-28 | Sandoz Ag | Adenosine derivatives, their preparation and use, and pharmaceutical preparations containing them |
| US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
| IT1275420B (it) | 1995-06-02 | 1997-08-05 | Schering Plough S P A | Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261 |
| WO1999034804A1 (en) | 1998-01-08 | 1999-07-15 | The University Of Virginia Patent Foundation | A2a adenosine receptor agonists |
| GB0228723D0 (en) * | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
| GB0305153D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Identification of therapeutic compounds |
-
2003
- 2003-03-07 GB GBGB0305149.7A patent/GB0305149D0/en not_active Ceased
-
2004
- 2004-03-05 ES ES04717707T patent/ES2310288T3/es not_active Expired - Lifetime
- 2004-03-05 PT PT04717707T patent/PT1603577E/pt unknown
- 2004-03-05 DK DK04717707T patent/DK1603577T3/da active
- 2004-03-05 KR KR1020057016699A patent/KR20050115273A/ko not_active Ceased
- 2004-03-05 PL PL04717707T patent/PL1603577T3/pl unknown
- 2004-03-05 EP EP04717707A patent/EP1603577B1/en not_active Expired - Lifetime
- 2004-03-05 CN CN200480004454A patent/CN100579533C/zh not_active Expired - Fee Related
- 2004-03-05 SI SI200430876T patent/SI1603577T1/sl unknown
- 2004-03-05 NZ NZ541521A patent/NZ541521A/en unknown
- 2004-03-05 JP JP2006505920A patent/JP2006519823A/ja active Pending
- 2004-03-05 CA CA002514098A patent/CA2514098A1/en not_active Abandoned
- 2004-03-05 DE DE602004015085T patent/DE602004015085D1/de not_active Expired - Lifetime
- 2004-03-05 AU AU2004216889A patent/AU2004216889B2/en not_active Ceased
- 2004-03-05 WO PCT/GB2004/000935 patent/WO2004078183A1/en not_active Ceased
- 2004-03-05 AT AT04717707T patent/ATE401087T1/de not_active IP Right Cessation
- 2004-03-05 US US10/547,455 patent/US7759321B2/en not_active Expired - Fee Related
-
2005
- 2005-09-27 NO NO20054476A patent/NO20054476L/no not_active Application Discontinuation
-
2008
- 2008-10-15 CY CY20081101141T patent/CY1108416T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006519823A5 (enExample) | ||
| JP2011132229A5 (enExample) | ||
| CN100579533C (zh) | 治疗疼痛的化合物 | |
| JP4836454B2 (ja) | 疼痛、特に痛覚過敏治療のための、スポンゴシン（２−メトキシアデノシン）の使用。 | |
| JP2006514638A5 (enExample) | ||
| EA032263B1 (ru) | Применение ингибиторов ccr3 | |
| EP1621195A3 (en) | The use of pyridinic NK-1 receptor antagonists for the treatment of brain, spinal or nerve injury | |
| JP2006519824A5 (enExample) | ||
| CA2671470A1 (en) | Powder formulation for valganciclovir | |
| JP6775699B2 (ja) | インドール化合物を用いた疼痛又は間質性膀胱炎の治療方法 | |
| RU2013157928A (ru) | Терапевтические средства для регуляции уровня фосфора в сыворотке | |
| ES2311537T3 (es) | Utilizacion de nefiracetam en el tratamiento de la neurodegeneracion postquemica. | |
| Wein et al. | Diabetic neuropathies | |
| ES2270981T3 (es) | Procedimiento de tratamiento de la neurodegeneracion. | |
| JP2010536827A (ja) | ある種の炎症性障害の治療に有用なカルボニルアミノ誘導体 | |
| JP2023545788A (ja) | ジヒドロオロト酸デヒドロゲナーゼ（ｄｈｏｄｈ）阻害剤による自己免疫疾患の治療 | |
| JP6857619B2 (ja) | Ｎ−［７−［（メチルスルホニル）アミノ］−４−オキソ−６−フェノキシ−４ｈ−１−ベンゾピラン−３−イル］ホルムアミドまたはその塩を含有する医薬組成物 | |
| EA008927B1 (ru) | Применение производных 2h-[1,3]оксазино[3,2-a]индола для лечения невропатической боли | |
| JP5699030B2 (ja) | エタネルセプトを含む線維筋痛症の治療剤 | |
| US20100179176A1 (en) | V3 antagonists for the treatment or prevention of chronic pain | |
| HK1087629B (en) | Compounds for the treatment of pain | |
| CN1809356A (zh) | 吲唑衍生物用于治疗神经病性疼痛的用途 | |
| RU2021123406A (ru) | Способы лечения состояний, связанных с рецептором s1p1 | |
| CN116940359A (zh) | 用二氢乳清酸脱氢酶（dhodh）抑制剂治疗自身免疫病 | |
| HK1086186B (en) | Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain |